Chen Schor


Mr. Schor has served as a member of our Board of Directors since November 2020.  Mr. Schor has served as  the President, Chief Executive Officer and Director of Adicet Bio, Inc. since September 2020.  He held the role of President and Chief Executive Officer at resTORbio since co-founding the company in 2016 until its merger with Adicet Bio in September 2020. Mr. Schor has led biotech companies across all stages, from formation and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant (CPA).